Clinical trials: Neoplasm, Oral
Dysphagia, Pain
Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer
This randomized pilot clinical trial studies dexamethasone in reducing oral pain and dry mouth after surgery in patients with oropharyngeal cancer. Dexamethasone may help lower pain and dry mouth caused by surgery.
- Conditions
- Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT01748942
- Testing
- Dexamethasone, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- OHSU Knight Cancer Institute
Neoplasms, Oral, Mouth Neoplasms
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery.
- Trial name
- NCT01553851
- Testing
- GSK1120212
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Breast Neoplasms
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast…
- Trial name
- NCT01740427
- Testing
- PD-0332991, Letrozole
- Where
- 305 sites in United States, Australia and 16 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Non-hematologic Malignancy
A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies
The purposes of this study are to evaluate the safety and tolerability of sapanisertib (MLN0128) milled active pharmaceutical ingredient (API) capsules administered both as a single agent and in combination with paclitaxel, to…
- Trial name
- NCT02412722
- Testing
- Sapanisertib, Paclitaxel
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostate Cancer
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer
The objective of the study is to determine if men with evidence of progressive prostate cancer while on chronic androgen ablation of ≥ 1 year duration will exhibit a clinical response following administration of parenteral…
- Trial name
- NCT01084759
- Testing
- Testosterone injection, Etoposide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma
Stereotactic Body Radiotherapy for Head and Neck Tumors
This study will evaluate the local control rates as well as acute and late toxicity rates of stereotactic body radiotherapy (SBRT) for the treatment of benign and malignant head and neck tumors.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Salivary Gland Cancer, Head and Neck Sarcoma
- Trial name
- NCT01344356
- Testing
- stereotactic body radiotherapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mercy Research
Neoplasms
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of BI 6727 in combination with fixed dose BIBF 1120, in patients with advanced or metastatic solid…
- Trial name
- NCT01022853
- Testing
- BI 6727, BIBF 1120
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
This randomized phase III trial is studying how well Caphosol rinse works in preventing mucositis in young patients undergoing autologous or donor stem cell transplant.
- Conditions
- Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes
- Trial name
- NCT01305200
- Testing
- supersaturated calcium phosphate rinse, questionnaire administration, quality-of-life assessment
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 226 people
- Sponsor
- Children's Oncology Group
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer
This phase II trials studies the side effects and how well ESK981 works in treating patients with castration-resistant prostate cancer that has spread to other places in the body.
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, PSA Progression
- Trial name
- NCT03456804
- Testing
- ESK981
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lymphoma
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy, such as clofarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00691652
- Testing
- rituximab, clofarabine, DNA methylation analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer, Metastatic Breast Cancer
Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer
This is a phase II single arm, open-label study of SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in metastatic HR+/HER2- breast cancer.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Hormone Receptor Positive Breast Carcinoma
- Trial name
- OASIS (NCT04720664)
- Testing
- SM-88
- Where
- 5 sites in United States
- Volunteers
- 11 people
- Sponsor
- Georgetown University
Myelofibrosis, Polycythemia Vera
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia…
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocytosis
- Trial name
- NCT00509899
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
Prostate Cancer
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive…
- Trial name
- NCT00428714
- Testing
- enzastaurin
- Where
- 11 sites in United States
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen
This study will compare PF-00299804 given orally on continuous schedule to the approved drug, erlotinib, in patients whose non-small cell lung cancer has progressed after chemotherapy; patients will be randomized to receive one…
- Trial name
- NCT00769067
- Testing
- Erlotinib, PF-00299804
- Where
- 59 sites in United States, Australia and 10 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Salivary Gland Neoplasms
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
The purpose of the study is to evaluate the overall response rate (ORR) of apalutamide in combination with a gonadotropin-releasing hormone (GnRH) agonist in participants with androgen receptor (AR) expressing locally advanced or…
- Trial name
- YATAGARASU (NCT04325828)
- Testing
- Apalutamide, GnRH Agonist
- Where
- 7 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Janssen Pharmaceutical K.K.
Cancer, Venous Thromboembolism
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients.
- Conditions
- Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- CANVAS (NCT02744092)
- Testing
- Rivaroxaban, Apixaban, Edoxaban
- Where
- 151 sites in United States
- Volunteers
- 811 people
- Sponsor
- Alliance Foundation Trials, LLC.
Prostate Cancer
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did…
- Trial name
- NRR (NCT00246753)
- Testing
- lapatinib ditosylate
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Hepatocellular Carcinoma (HCC), Solid Malignancies
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid…
- Trial name
- NCT02325739
- Testing
- FGF401, PDR001
- Where
- 27 sites in United States, China and 9 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
UAB 0718 - Phase II Trial to Assess Target Oral Therapy as Adjuvant Chemoprevention in High-Risk Head and Neck Cancer
The purpose of this study is to determine whether erlotinib will be effective in controlling cancer that has returned after treatment with salvage surgery and radiation.
- Trial name
- UAB0718 (NCT00570232)
- Testing
- Erlotinib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Alabama at Birmingham
Cancer of the Pharynx, Cancer of the Larynx
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
The combined use of chemotherapeutic drugs with radiation has proven to be effective in improving overall survival and local control among patients with locally advanced head and neck cancer.
- Conditions
- Cancer of the Pharynx, Cancer of the Larynx, Cancer of the Nasal Cavity, Paranasal Sinus Neoplasms
- Trial name
- DeCIDE (NCT00117572)
- Testing
- docetaxel, cisplatin, hydroxyurea
- Where
- 26 sites in United States, Croatia and 3 more
- Volunteers
- 285 people
- Sponsor
- University of Chicago